Protein Inhibitor of Type VI-B CRISPR-Cas System

Tech ID: 32275 / UC Case 2021-101-0

Patent Status

Patent Pending

Brief Description

The inventors have discovered the first protein inhibitor of the type VI-B CRISPR-Cas system. By controlling this CRISPR system, one could possibly ameliorate the toxicity and off-target cleavage activity observed with the use of the type VI CRISPR system. Moreover, these proteins can also serve as an antidote for instances where the use of CRISPR-Cas technology poses a safety risk. Additionally, this technology can also be used for engineering genetic circuits in mammalian cells. This finding is of potential importance to many companies in the CRISPR space.


 

Suggested uses

This technology will enable safe and precise use of CRISPR-Cas type VI-B.

The invention can also be used for engineering gene circuits in mammalian cells.

Advantages

Many Anti-CRISPRs have been discovered for multiple DNA-targeting systems but none have been discovered for the RNA-targeting type VI-B CRISPR system that is widely being used for biotechnological applications in research, healthcare, agriculture, and vector control. 

Anti-CRISPRs are biomolecules that inhibit nucleic-acid targeting and/or cleavage by CRISPR-Cas systems. 
 

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Doudna, Jennifer A.

Other Information

Keywords

CRISPR

Categorized As

Additional Technologies by these Inventors